The FDA expanded approval for Bayer’s lung cancer drug in a move that broadens clinical use, according to coverage of the regulator’s latest action. The decision arrives as lung cancer developers continue to refine biomarker strategies and sequencing approaches across evolving standards of care. The update also signals ongoing efforts by regulators to keep clinical guidance aligned with new evidence, especially where prior label language can constrain adoption in community settings.